|
Price: $0.9400
$0.00 
0.000%
|
| Day's High:
| $0.94
| Week Perf:
| 13.25 %
|
| Day's Low: |
$ 0.91 |
30 Day Perf: |
2.29 % |
| Volume (M): |
3 |
52 Wk High: |
$ 1.75 |
| Volume (M$): |
$ 3 |
52 Wk Avg: |
$1.13 |
| Open: |
$0.92 |
52 Wk Low: |
$0.72 |
|
|
| Market Capitalization (Millions $) |
7 |
| Shares
Outstanding (Millions) |
7 |
| Employees |
54 |
| Revenues (TTM) (Millions $) |
19 |
| Net Income (TTM) (Millions $) |
-54 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Dss Inc
DSS Inc is a software development company that specializes in creating innovative solutions for the aerospace, defense, and natural resource industries. With over 30 years of experience, they have built a reputation for delivering high-quality software for complex and mission-critical systems. Their solutions include data analytics, decision support systems, and enterprise software integration. DSS Inc is committed to providing their clients with reliable and efficient software that helps them make better decisions and improve their operational processes.
Company Address: 275 Wiregrass Pkwy Henrietta 14586 NY
Company Phone Number: 325-3610 Stock Exchange / Ticker: NYSEAMER DSS
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Announcement
Published Mon, Sep 16 2024 8:26 PM UTC
NEW YORK, Sept. 16, 2024 In a significant milestone for both companies and their stakeholders, DSS, Inc. (NYSE American: DSS) has officially announced its delight over the successful initial public offering (IPO) of its dedicated partner and investment, Impact BioMedical Inc. (NYSE American: IBO). The IPO, priced at $3.00 per share, marks a pivotal moment for Impact BioMe...
|
| Dss Inc
/>In a recent financial report, DSS Inc. declared a disastrous fiscal span ending March 31, 2024. With a staggering decline of -67.552% in revenue to $3.87 million, and a net deficit per share expanding to $-0.58, DSS Inc. experienced a significant setback compared to the previous year. However, amidst these concerning figures, the company's investment in Impact Biomedical Inc. shows promising potential for the future.
Fact 1: USPTO Grants Patent for Low Glycemic Sugar Composition
Impact Biomedical, a company in which DSS Inc. holds a significant investment, recently obtained a groundbreaking patent from the U.S. Patent and Trademark Office (USPTO). The patent, numbered 11,898,184, focuses on the creation of a Low Glycemic Sugar Composition using Impact Biomedical's Laetose technology platform. This achievement underscores the company's commitment to providing alternative sugar options that have minimal impacts on blood sugar levels ? catering to the growing demand for healthier and diabetic-friendly sweeteners.
|
| Dss Inc
As a financial journalist for the prestigious , it is my duty to analyze and interpret the recent financial results of companies for our esteemed readers. Today, we turn our attention to Dss Inc and delve into their disastrous October to December 2023 quarter.
During this time frame, Dss Inc faced a significant decline in revenue, fading by a staggering 61.642% to $6.92 million. This decline was accompanied by a widened net deficit per share, which extended to $-0.22, compared to the similar quarter a year prior. However, it is worth noting that there was some improvement when compared to the previous quarter, where the net deficit per share stood at $-0.03.
|
| Product Service News
Published Tue, Jan 30 2024 1:06 PM UTC
In a groundbreaking development, Impact Biomedical Inc. (IBIO), a company in which DSS Inc. holds a significant investment, has achieved a major milestone with its proprietary Laetose technology platform. This exciting breakthrough comes in the form of a U.S. Patent Allowance, with the U.S. Patent and Trademark Office (USPTO) recently granting the company patent 11,898,184....
|
| Stock Market Announcement
Published Thu, Jan 4 2024 1:15 PM UTC
In a recent press release, DSS, Inc. announced that Chairman of the Board, Heng Fai Ambrose Chan, has acquired an impressive 672,173 shares of the company in the open market. This move aims to increase Chan s investment in the company, signaling strong confidence in its future prospects. These developments come at a time when DSS, Inc. has 140,140,913 million share...
|
| Per Share |
Current |
| Earnings (TTM) |
-6.62 $ |
| Revenues (TTM) |
2.63 $
|
| Cash Flow (TTM) |
- |
| Cash |
1.62 $
|
| Book Value |
4.63 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-6.62 $
|
| Revenues (TTM) |
2.63 $ |
| Cash Flow (TTM) |
- |
| Cash |
1.62 $
|
| Book Value |
4.63 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Product Packaging |
|
 86.55 % |
of total Revenue |
| Commercial Banking |
|
4.5 % |
of total Revenue |
| Direct Marketing Online Sales |
|
-0.04 % |
of total Revenue |
| Biotechnology |
|
0.18 % |
of total Revenue |
| Securities |
|
35.6 % |
of total Revenue |
| Printed Products |
|
86.23 % |
of total Revenue |
| Rental Revenue Income |
|
8.86 % |
of total Revenue |
| Commission Revenue |
|
4.11 % |
of total Revenue |
| Net Investment Revenue Income |
|
0.8 % |
of total Revenue |
| Packaging Printing and Fabrication Printed Products |
|
85.25 % |
of total Revenue |
| Commercial and Security Printing Printed Products |
|
0.98 % |
of total Revenue |
| Rental Income Rental Revenue Income |
|
8.86 % |
of total Revenue |
| Commission Income Commission Revenue |
|
4.11 % |
of total Revenue |
| Net Investment Income Net Investment Revenue Income |
|
0.8 % |
of total Revenue |
|
|
